RetinalGenix Technologies Inc.
RTGNDrugs in Pipeline
4
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
N-acetylcysteine
Retinitis Pigmentosa
ketoconazole
Chronic Central Serous Chorioretinopathy
Anecortave Acetate Sterile suspension 15 mg
Chronic Central Serous Chorioretinopathy
Metformin
Age-Related Macular Degeneration
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
N-acetylcysteine | Phase 3 | Retinitis Pigmentosa | - | - |
ketoconazole | Phase 2 | Chronic Central Serous Chorioretinopathy | - | - |
Anecortave Acetate Sterile suspension 15 mg | Phase 2 | Chronic Central Serous Chorioretinopathy | - | - |
Metformin | Phase 2 | Age-Related Macular Degeneration | - | - |
Frequently asked questions
What is in RetinalGenix Technologies Inc.'s drug pipeline?→
CatalystAlert tracks 4 drug candidates in RetinalGenix Technologies Inc.'s (RTGN) pipeline across Phase 3, Phase 2. Its lead program is N-acetylcysteine (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is RetinalGenix Technologies Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for RetinalGenix Technologies Inc. (RTGN) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track RTGN biotech catalysts?→
Add RTGN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow RetinalGenix Technologies Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.